Symbols / PROK $2.15 -4.44%
PROK Chart
About
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 646.79M |
| Enterprise Value | 1.36B | Income | -71.03M | Sales | 744.00K |
| Book/sh | -7.41 | Cash/sh | 1.92 | Dividend Yield | — |
| Payout | 0.00% | Employees | 204 | IPO | — |
| P/E | — | Forward P/E | -3.38 | PEG | — |
| P/S | 869.35 | P/B | -0.29 | P/C | — |
| EV/EBITDA | -8.28 | EV/Sales | 1832.25 | Quick Ratio | 9.39 |
| Current Ratio | 10.32 | Debt/Eq | 1.33 | LT Debt/Eq | — |
| EPS (ttm) | -0.55 | EPS next Y | -0.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 | ROA | -25.85% |
| ROE | -41.81% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -176.13% | Profit Margin | 0.00% | Shs Outstand | 141.55M |
| Shs Float | 93.27M | Short Float | 15.13% | Short Ratio | 19.19 |
| Short Interest | — | 52W High | 7.13 | 52W Low | 0.46 |
| Beta | 1.80 | Avg Volume | 905.55K | Volume | 623.76K |
| Target Price | $6.25 | Recom | Buy | Prev Close | $2.25 |
| Price | $2.15 | Change | -4.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.25
Mean price target
2. Current target
$2.15
Latest analyst target
3. DCF / Fair value
$-13.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.15
Low
$1.00
High
$12.00
Mean
$6.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-16 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2025-07-15 | main | UBS | Buy → Buy | $8 |
| 2025-07-14 | main | Guggenheim | Buy → Buy | $7 |
| 2025-07-09 | main | Citigroup | Buy → Buy | $9 |
| 2025-06-30 | down | B of A Securities | Neutral → Underperform | $1 |
| 2024-09-30 | init | JP Morgan | — → Neutral | — |
| 2024-09-10 | init | Guggenheim | — → Buy | $6 |
| 2024-09-04 | main | B of A Securities | Neutral → Neutral | $3 |
| 2024-06-10 | main | Jefferies | Buy → Buy | $6 |
| 2024-05-29 | main | B of A Securities | Neutral → Neutral | $4 |
| 2024-01-02 | down | B of A Securities | Buy → Neutral | $2 |
| 2023-07-25 | init | BTIG | — → Buy | $16 |
| 2022-12-21 | init | Jefferies | — → Buy | $15 |
| 2022-11-10 | init | Morgan Stanley | — → Equal-Weight | $13 |
| 2022-10-18 | init | UBS | — → Buy | $18 |
| 2022-10-14 | init | Citigroup | — → Buy | $16 |
| 2022-09-02 | init | Evercore ISI Group | — → Outperform | — |
- ProKidney (NASDAQ:PROK) Stock Price Down 4.7% - Time to Sell? - MarketBeat Mon, 16 Mar 2026 19
- ProKidney (NASDAQ: PROK) CEO awarded stock options on 3,000,000 shares - Stock Titan ue, 03 Mar 2026 08
- ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK) - Seeking Alpha Sat, 31 Jan 2026 08
- $PROK stock is down 12% today. Here's what we see in our data. - Quiver Quantitative Mon, 29 Dec 2025 08
- ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright - Yahoo Finance Sat, 27 Dec 2025 08
- ProKidney: What's Happening With PROK Stock? - Forbes Wed, 09 Jul 2025 07
- What’s Behind The 500% Rise In ProKidney Stock? - Trefis Wed, 09 Jul 2025 07
- Individual investors who hold 32% of ProKidney Corp. (NASDAQ:PROK) gained 560%, institutions profited as well - simplywall.st Wed, 09 Jul 2025 07
- ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewswire Mon, 10 Nov 2025 08
- ProKidney Corp. (NASDAQ:PROK) Given Average Rating of "Hold" by Analysts - MarketBeat Wed, 25 Feb 2026 08
- ProKidney Is Soaring on Trial Results. How Should You Play Penny Stock PROK Here? - Yahoo Finance ue, 08 Jul 2025 07
- Late‑Breaking Phase 2 REGEN‑007 Results: ProKidney to Present Two Posters at ASN Kidney Week Nov 6 - Stock Titan Mon, 20 Oct 2025 07
- ProKidney (NASDAQ:PROK) Stock Price Up 9% - Here's Why - MarketBeat Wed, 04 Mar 2026 08
- PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance hu, 17 Jul 2025 07
- ProKidney (Nasdaq: PROK) Nov 12 Guggenheim chat webcast; to join Jefferies meetings - Stock Titan Wed, 29 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 757162 | 1884577.0 | — | Sale at price 2.37 - 2.72 per share. | PEREIRA BRIAN J G | Director | — | 2025-11-13 00:00:00 | I |
| 1 | 103480 | 312510.0 | — | Sale at price 3.02 per share. | WEBER DARIN J. | Officer | — | 2025-07-08 00:00:00 | D |
| 2 | 3823996 | nan | — | — | LEGORRETA PABLO G | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-03 00:00:00 | I |
| 3 | 387393 | 276366.0 | — | Purchase at price 0.71 per share. | CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-22 00:00:00 | D |
| 4 | 25000 | 18690.0 | — | Purchase at price 0.75 per share. | CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-17 00:00:00 | D |
| 5 | 100000 | 74820.0 | — | Purchase at price 0.75 per share. | CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-16 00:00:00 | D |
| 6 | 736105 | 520599.0 | — | Purchase at price 0.70 - 0.73 per share. | CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-15 00:00:00 | D |
| 7 | 1034118 | 628847.0 | — | Purchase at price 0.61 per share. | CONTROL EMPRESARIAL DE CAPITALES, S.A. DE C.V. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-11 00:00:00 | D |
| 8 | 757162 | nan | — | — | PEREIRA BRIAN J G | Director | — | 2025-02-04 00:00:00 | D/I |
| 9 | 532535 | nan | — | — | LEGORRETA PABLO G | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-02-04 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -158.49M | -125.59M | -143.99M | -53.12M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -61.19M | -35.47M | -108.03M | -55.15M |
| ReconciledDepreciation | 5.43M | 3.85M | 3.04M | 1.98M |
| EBITDA | -158.49M | -125.59M | -143.99M | -53.12M |
| EBIT | -163.92M | -129.44M | -147.02M | -55.11M |
| NetInterestIncome | 19.74M | 22.07M | 5.77M | 2.00K |
| InterestExpense | 9.00K | 12.00K | 215.00K | 0.00 |
| InterestIncome | 19.75M | 22.08M | 5.98M | 2.00K |
| NormalizedIncome | -61.19M | -35.47M | -108.03M | -55.15M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -61.19M | -35.47M | -108.03M | -55.15M |
| TotalExpenses | 183.75M | 151.52M | 153.01M | 55.11M |
| TotalOperatingIncomeAsReported | -183.68M | -151.52M | -153.01M | -55.11M |
| DilutedAverageShares | 97.92M | 61.71M | 61.54M | 186.50M |
| BasicAverageShares | 97.92M | 61.71M | 61.54M | 186.50M |
| DilutedEPS | -0.62 | -0.57 | -0.23 | -0.30 |
| BasicEPS | -0.62 | -0.57 | -0.23 | -0.30 |
| DilutedNIAvailtoComStockholders | -61.19M | -35.47M | -108.03M | -55.15M |
| NetIncomeCommonStockholders | -61.19M | -35.47M | -108.03M | -55.15M |
| NetIncome | -61.19M | -35.47M | -108.03M | -55.15M |
| MinorityInterests | 102.15M | 99.98M | 40.10M | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -163.34M | -135.45M | -148.13M | -55.15M |
| NetIncomeContinuousOperations | -163.34M | -135.45M | -148.13M | -55.15M |
| TaxProvision | -598.00K | 6.00M | 896.00K | 38.00K |
| PretaxIncome | -163.93M | -129.45M | -147.24M | -55.11M |
| NetNonOperatingInterestIncomeExpense | 19.74M | 22.07M | 5.77M | 2.00K |
| InterestExpenseNonOperating | 9.00K | 12.00K | 215.00K | 0.00 |
| InterestIncomeNonOperating | 19.75M | 22.08M | 5.98M | 2.00K |
| OperatingIncome | -183.68M | -151.52M | -153.01M | -55.11M |
| OperatingExpense | 183.75M | 151.52M | 153.01M | 55.11M |
| ResearchAndDevelopment | 127.67M | 106.71M | 82.07M | 46.26M |
| SellingGeneralAndAdministration | 56.08M | 44.81M | 70.94M | 8.86M |
| GeneralAndAdministrativeExpense | 56.08M | 44.81M | 70.94M | 8.86M |
| OtherGandA | 56.08M | 44.81M | 70.94M | 8.86M |
| TotalRevenue | 76.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 76.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 128.05M | 59.88M | 61.54M | 61.54M |
| ShareIssued | 128.05M | 59.88M | 61.54M | 61.54M |
| TotalDebt | 3.24M | 4.41M | 2.40M | 1.33M |
| TangibleBookValue | -994.95M | -1.10B | -1.10B | 26.49M |
| InvestedCapital | -994.95M | -1.10B | -1.10B | 26.92M |
| WorkingCapital | 359.67M | 349.11M | 493.85M | 14.96M |
| NetTangibleAssets | -994.95M | -1.10B | -1.10B | 26.49M |
| CapitalLeaseObligations | 3.24M | 4.41M | 2.40M | 1.33M |
| CommonStockEquity | -994.95M | -1.10B | -1.10B | 26.92M |
| TotalCapitalization | -994.95M | -1.10B | -1.10B | 26.92M |
| TotalEquityGrossMinorityInterest | 401.64M | 391.34M | 504.94M | 26.92M |
| MinorityInterest | 1.40B | 1.49B | 1.60B | 0.00 |
| StockholdersEquity | -994.95M | -1.10B | -1.10B | 26.92M |
| GainsLossesNotAffectingRetainedEarnings | 130.00K | 130.00K | 0.00 | |
| OtherEquityAdjustments | 130.00K | 130.00K | ||
| RetainedEarnings | -1.20B | -1.14B | -1.10B | -161.51M |
| AdditionalPaidInCapital | 205.74M | 36.11M | 7.48M | 0.00 |
| CapitalStock | 29.00K | 23.00K | 24.00K | 188.43M |
| CommonStock | 29.00K | 23.00K | 24.00K | 188.43M |
| TotalPartnershipCapital | 26.92M | |||
| LimitedPartnershipCapital | 188.43M | |||
| TotalLiabilitiesNetMinorityInterest | 39.44M | 29.22M | 13.06M | 13.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.22M | 4.18M | 2.18M | 1.07M |
| TradeandOtherPayablesNonCurrent | 748.00K | 568.00K | 278.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 2.47M | 3.61M | 1.91M | 1.07M |
| LongTermCapitalLeaseObligation | 2.47M | 3.61M | 1.91M | 1.07M |
| CurrentLiabilities | 36.22M | 25.04M | 10.87M | 12.31M |
| CurrentDebtAndCapitalLeaseObligation | 765.00K | 803.00K | 493.00K | 267.00K |
| CurrentCapitalLeaseObligation | 765.00K | 803.00K | 493.00K | 267.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.45M | 7.52M | 3.35M | 1.83M |
| PayablesAndAccruedExpenses | 24.00M | 16.71M | 7.03M | 10.21M |
| CurrentAccruedExpenses | 19.68M | 10.14M | 3.98M | 7.38M |
| Payables | 4.32M | 6.57M | 3.04M | 2.83M |
| TotalTaxPayable | 682.00K | 1.47M | 0.00 | |
| IncomeTaxPayable | 682.00K | 1.47M | 0.00 | |
| AccountsPayable | 3.63M | 5.10M | 3.04M | 2.83M |
| TotalAssets | 441.07M | 420.55M | 518.00M | 40.30M |
| TotalNonCurrentAssets | 45.19M | 46.41M | 13.28M | 13.03M |
| GoodwillAndOtherIntangibleAssets | 0.00 | 213.00K | 428.00K | |
| NetPPE | 45.19M | 46.41M | 13.06M | 12.60M |
| AccumulatedDepreciation | -11.03M | -7.64M | -4.71M | -2.26M |
| GrossPPE | 56.22M | 54.05M | 17.77M | 14.86M |
| Leases | 21.82M | 10.95M | 10.54M | 10.52M |
| ConstructionInProgress | 2.45M | 8.74M | 1.61M | 351.00K |
| OtherProperties | 2.97M | 4.26M | 2.36M | 1.24M |
| MachineryFurnitureEquipment | 6.49M | 4.54M | 3.27M | 2.75M |
| BuildingsAndImprovements | 21.09M | 22.49M | 0.00 | |
| LandAndImprovements | 1.41M | 3.07M | 0.00 | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 395.88M | 374.15M | 504.72M | 27.27M |
| OtherCurrentAssets | 80.00K | 9.00K | 1.38M | 25.00K |
| AssetsHeldForSaleCurrent | 19.37M | 0.00 | ||
| PrepaidAssets | 15.70M | 9.81M | 13.08M | 6.69M |
| Receivables | 2.45M | 1.38M | 0.00 | |
| AccruedInterestReceivable | 2.45M | 1.38M | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 358.29M | 362.95M | 490.25M | 20.56M |
| OtherShortTermInvestments | 259.17M | 302.30M | 0.00 | |
| CashAndCashEquivalents | 99.12M | 60.65M | 490.25M | 20.56M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -155.86M | -124.27M | -78.94M | -55.49M |
| RepurchaseOfCapitalStock | 0.00 | -9.50M | 0.00 | 0.00 |
| RepaymentOfDebt | -54.00K | -52.00K | -35.03M | -30.00K |
| IssuanceOfDebt | 0.00 | 0.00 | 35.00M | 0.00 |
| IssuanceOfCapitalStock | 144.32M | 0.00 | 0.00 | |
| CapitalExpenditure | -29.51M | -34.20M | -1.85M | -5.19M |
| IncomeTaxPaidSupplementalData | 73.00K | 2.86M | 1.95M | 68.00K |
| EndCashPosition | 99.12M | 60.65M | 490.25M | 20.56M |
| BeginningCashPosition | 60.65M | 490.25M | 20.56M | 4.58M |
| ChangesInCash | 38.47M | -429.60M | 469.69M | 15.98M |
| FinancingCashFlow | 144.41M | -9.55M | 548.52M | 71.47M |
| CashFlowFromContinuingFinancingActivities | 144.41M | -9.55M | 548.52M | 71.47M |
| NetOtherFinancingCharges | 548.55M | 71.50M | ||
| ProceedsFromStockOptionExercised | 140.00K | 0.00 | 0.00 | |
| NetCommonStockIssuance | 144.32M | -9.50M | 0.00 | 0.00 |
| CommonStockPayments | 0.00 | -9.50M | 0.00 | 0.00 |
| CommonStockIssuance | 144.32M | 0.00 | 0.00 | |
| NetIssuancePaymentsOfDebt | -54.00K | -52.00K | -32.00K | -30.00K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | 0.00 | 0.00 |
| ShortTermDebtPayments | 0.00 | 0.00 | -35.00M | 0.00 |
| ShortTermDebtIssuance | 0.00 | 0.00 | 35.00M | 0.00 |
| NetLongTermDebtIssuance | -54.00K | -52.00K | -32.00K | -30.00K |
| LongTermDebtPayments | -54.00K | -52.00K | -32.00K | -30.00K |
| InvestingCashFlow | 20.41M | -329.98M | -1.74M | -5.19M |
| CashFlowFromContinuingInvestingActivities | 20.41M | -329.98M | -1.74M | -5.19M |
| NetOtherInvestingChanges | 108.00K | |||
| NetInvestmentPurchaseAndSale | 49.92M | -295.79M | 0.00 | 0.00 |
| SaleOfInvestment | 373.95M | 175.82M | 0.00 | 0.00 |
| PurchaseOfInvestment | -324.02M | -471.60M | 0.00 | 0.00 |
| NetPPEPurchaseAndSale | -29.51M | -34.20M | -1.85M | -5.19M |
| SaleOfPPE | 0.00 | 0.00 | 1.00K | |
| PurchaseOfPPE | -29.51M | -34.20M | -1.85M | -5.19M |
| OperatingCashFlow | -126.35M | -90.07M | -77.09M | -50.30M |
| CashFlowFromContinuingOperatingActivities | -126.35M | -90.07M | -77.09M | -50.30M |
| ChangeInWorkingCapital | 3.96M | 16.67M | -6.46M | 2.16M |
| ChangeInOtherCurrentAssets | -5.70M | |||
| ChangeInPayablesAndAccruedExpense | 10.98M | 13.40M | 772.00K | 7.87M |
| ChangeInPayable | 10.98M | 13.40M | 772.00K | 7.87M |
| ChangeInAccountPayable | 11.59M | 11.64M | 494.00K | 7.87M |
| ChangeInTaxPayable | -609.00K | 1.76M | 278.00K | 0.00 |
| ChangeInIncomeTaxPayable | -609.00K | 1.76M | 278.00K | 0.00 |
| ChangeInPrepaidAssets | -5.96M | 4.65M | -7.23M | -5.70M |
| ChangeInReceivables | -1.07M | -1.38M | 0.00 | 0.00 |
| OtherNonCashItems | -161.00K | |||
| StockBasedCompensation | 29.37M | 30.85M | 74.47M | 699.00K |
| AssetImpairmentCharge | 5.32M | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 5.43M | 3.85M | 3.04M | 1.98M |
| DepreciationAndAmortization | 5.43M | 3.85M | 3.04M | 1.98M |
| OperatingGainsLosses | -6.94M | -6.00M | ||
| GainLossOnInvestmentSecurities | -7.00M | -6.02M | ||
| GainLossOnSaleOfPPE | 56.00K | 23.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -163.34M | -135.45M | -148.13M | -55.15M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PROK
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|